For Immediate Release

Chicago, IL – November 23, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pozen (POZN), Sanofi-Aventis (SNY), Bristol-Myers (BMY), AstraZeneca (AZN) and ADC Telecommunications Inc. (ADCT).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Friday’s Analyst Blog:

Pozen Initiates New Phase III

This morning, Pozen (POZN) initiated phase III studies on PA-325/40, a fixed-dose combination of 325mg enteric coated aspirin and 40mg of immediate release omeprazole. The phase III program will consist of two pivotal trials conducted under a Special Protocol Assessment (SPA) agreed upon with

...

This morning, Pozen (POZN) initiated phase III studies on PA-325/40, a fixed-dose combination of 325mg enteric coated aspirin and 40mg of immediate release omeprazole. The phase III program will consist of two pivotal trials conducted under a Special Protocol Assessment (SPA) agreed upon with the U.S. FDA, and one long-term safety study. The two pivotal programs will enroll approximately 500 patients per study at over 100 sites around the U.S. The primary endpoint of the pivotal studies is the cumulative incidence of gastric ulcers over the six-month treatment period for PA32540 versus 325 mg of enteric-coated aspirin. The long-term study will enroll approximately 400 patients and assess safety over a period of one year. Pozen is developing PA-325/40 for use in the secondary prevention of heart attacks and strokes in patients at risk for associated gastric ulcers. Aspirin is the No. 1 recommended agent for at-risk ...

Vimovo Demonstrates Benefit Over Naproxen Yesterday, at the American College of Gastroenterology meeting in San Diego, Pozen (POZN) released data from two phase III trials comparing Vimovo (formerly PN400) to enteric-coasted naproxen (ECN) in patients with osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis (AS) who are at risk of developing NSAID-associated gastric ulcers. The data demonstrated that patients taking Vimovo experienced significantly greater reduction in severity of dyspepsia (SODA) and overall treatment evaluation for dyspepsia (OTE-DP) compared to patients taking ECN. The OTE-DP results showed 43-46% of the patients on Vimovo reporting positive change at month six vs. only 28-34% on ECN. The results were highly statistically significant. Plus, patients taking Vimovo also had discontinuation rates far below ECN, at 3-5% vs. 11-12%, respectively. The safety of Vimovo was also superior to ECN, with only 2% of the patients experiencing erosive duodenitis as compared to 10-14% for ...

Adeona Pharmaceuticals, Inc.

(Public, AMEX:AEN)

StocksHaven Investments takes a look at Adeona Pharmaceuticals, Inc. which currently has three blockbuster drugs in phase III, and are coming close to NDA status. The first being Trimesta, which tackles Multiple Sclerosis (MS) and Post-partum Depression. Secondly, Zinthionein, a product seeking treatment for Age Related Macular Degeneration (AMD). Lastly, Oral dnaJP1 which is an immunotherapy for rheumatoid arthritis (RA) patients. If these products aren’t enough to entice your way into purchasing this stock, take a look at the recent $5 million dollar cash infusion from the National Multiple Sclerosis Society (NMSS), billions of dollars in product market potential, purchasing of Hartlab LLC, an independent Chicago-area CLIA-certified clinical reference laboratory, an experienced management team that will have you feeling like a kid in a candy store, and to

...

Fiscal 2009 third quarter financial performance remains strong Myriad Genetics, Inc. (MYGN) relies on its molecular diagnostic products for its revenue generation and is currently seeing solid growth in this business. On May 4, 2009, the company reported fiscal 3Q09 financial results ended March 31, 2009.Total revenue for the 2009 fiscal third quarter increased to a record $87.5 million, compared with $61.8 million in the prior-year period. Molecular diagnostic revenues rose 47% to $86.5 million from $59.0 million last year. The improvement resulted primarily from an increase in the Company's sales and marketing efforts, including expansion of its women's health sales force. It was also due to the continuation of its direct-to-consumer marketing campaign, which the company believes has resulted in improved physician acceptance and adoption of its molecular diagnostic products. Molecular diagnostic revenue of $86.5 million in 3Q09 was slightly lower than our ...

Buy Rating Maintained for Myriad Genetics in Anticipation of Another Strong Quarter We maintain our Buy rating for Myriad Genetics (MYGN) in anticipation of strong fiscal third quarter performance ending March 31, 2009. We also raise our price target to $53 from original $50 based on recent recommendation by the American College of Obstetricians and Gynecologists (ACOG) that routine screening for Hereditary Breast and Ovarian Cancer should performed. The new price target also reflects the two for one stock split effective on March 25, 2009.  Myriad Genetics will report its fiscal third quarter results early next month. We maintain our optimism on the predictive medicine and believe this business will keep recording double-digit growth in the coming years. Revenue will grow at a CAGR of 31% during the 2009-2012 periods while EPS will maintain a CAGR of 39% during the 2009-2012 periods....

For Immediate Release

Chicago, IL - April 7, 2009 - Zacks Equity Research picks UDR, Inc. (UDR) as Bull of the Day and Hartford Financial Services (HIG) as Bear of the Day. In addition, the analysts at Zacks Equity Research discuss the latest on Abbott Laboratories (ABT), Boston Scientific Inc.'s (BSX) and Peabody Energy Corp. (BTU).

Full analysis of all these stocks is available at: http://at.zacks.com/?id=2678

Bull of the Day

UDR, Inc. (UDR) is an apartment real estate investment trust (REIT) that owns, operates, acquires, develops and renovates middle-market apartment communities. Although it has assets across the country, UDR's exposure is mostly in the Western and Mid-Atlantic U.S.

2009 will be a more difficult year for multi-family REITs; the lack of job growth will force landlords to cut rents and offer more concessions. In a recessionary environment, we

...

For Immediate Release

Chicago, IL - March 27, 2009 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: PepsiCo (PEP), Dr. Pepper Snapple Group (DPS), Auxilium Pharmaceuticals (AUXL), Myriad Genetics (MYGN) and Autoliv, Inc. (ALV).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579.

Here are highlights from Thursday's Analyst Blog:

Dr. Pepper Plants a Kiss

Product innovation is a key to growing or sometimes maintaining market share for consumer companies. Just as PepsiCo (PEP) is about to introduce Pepsi Natural, Pepsi Throwback and Mountain Dew Throwback, Dr. Pepper Snapple Group (DPS)

...

On March 20, 2009, the American College of Obstetricians and Gynecologists (ACOG) disclosed a news release that its Practice Bulletin #103 "Hereditary Breast and Ovarian Cancer Syndrome" has been published in the April 2009 edition of Obstetrics & Gynecology. In the Bulletin, the ACOG recommended routine screening for Hereditary Breast and Ovarian Cancer. ACOG has over 52,000 members, and is the nation's leading group of professionals providing health care for women.Following the publication of the bulletin, on March 24, Myriad Genetics (MYGN) disclosed a news release applauding the recommendation of routine screening for Hereditary Breast and Ovarian Cancer.  As a result of the news release, MYGN shares shot up about 8% in the morning trading session.There is a reason for MYGN price appreciation on the news release. Keep in mind, Myriad Genetics is a biopharmaceutical company that focuses on the development of diagnostic and therapeutic ...

Today before the opening bell, Northfield Laboratories announced that the U.S. FDA has approved the filing of the Biologics License Application (BLA) for PolyHeme®, the company’s investigative human hemoglobin-based red cell substitute developed to treat life-threatening red blood cell loss when red blood cells are not available. The company also announced that the FDA has chosen the submission for Priority Review, with the intention to review the application by April 30, 2009.

Steven A. Gould, M.D., Chairman and Chief Executive Officer, stated, “Filing of our BLA for PolyHeme with Priority Review is a key milestone for Northfield. We are now one step closer to delivering a potential life-saving therapy to patients who need transfusion in situations when blood is not available.”

Northfield submitted the BLA for PolyHeme on October 29, 2008, based on its inclusive development program, including data from its Multicenter Phase III randomized, double-blind trial involving 720 trauma patients. Conclusions

...